Celgene Corp (CELG-Q) Stock Predictions - Stockchase
WATCH LIST
79
Celgene Corp (CELG-Q)

ON STOCKCHASE SINCE Jan 2012

Consumer Products

Celgene Corp

CELG-Q

17 watching          
Join the Discussion

Celgene Corp (CELG-Q) SAVE Dec, 10, 2018, 8:28 pm

68.68 1.4 (2%)

About Celgene Corp (CELG-Q)

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. More at Wikipedia

What the experts are saying about CELG-Q



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
Celgene Corp(CELG-Q) 

December 3, 2018

They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Consumer Products
0 0 0 0 0
0 comments
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Consumer Products
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$73.420
Owned Owned
Yes

DON'T BUY
Celgene Corp(CELG-Q) 

November 12, 2018

They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
Consumer Products
0 0 0 0 0
0 comments
They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
Consumer Products
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$71.020
Owned Owned
Unknown

TOP PICK
Celgene Corp(CELG-Q) 

October 22, 2018

(no dividend yield, Analysts' price target: not given)  A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

Consumer Products
0 0 0 0 0
0 comments

(no dividend yield, Analysts' price target: not given)  A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

Consumer Products
0 0 0 0 0
0 comments
Ashley Misquitt

Senior Po, Empire Life ...

Price Price
$80.610
Owned Owned
Yes

DON'T BUY
Celgene Corp(CELG-Q) 

October 10, 2018

They have a good cash float, which will lead to a share buyback, he feels.   He sees resistance at $90-$100, which will be tough to battle through.  He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise.  He would prefer IHI-N if you like the healthcare space as he does.  

Consumer Products
0 0 0 0 0
0 comments

They have a good cash float, which will lead to a share buyback, he feels.   He sees resistance at $90-$100, which will be tough to battle through.  He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise.  He would prefer IHI-N if you like the healthcare space as he does.  

Consumer Products
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$84.230
Owned Owned
No

DON'T BUY
Celgene Corp(CELG-Q) 

September 18, 2018

They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.

Consumer Products
0 0 0 0 0
0 comments

They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.

Consumer Products
0 0 0 0 0
0 comments
John O'Connell,

Chairman a, Davis Rea...

Price Price
$87.610
Owned Owned
No

HOLD
Celgene Corp(CELG-Q) 

September 12, 2018

Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.

Consumer Products
0 0 0 0 0
0 comments

Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.

Consumer Products
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$86.800
Owned Owned
No

PAST TOP PICK
Celgene Corp(CELG-Q) 

August 21, 2018

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

Consumer Products
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$91.200
Owned Owned
Yes

PARTIAL BUY
Celgene Corp(CELG-Q) 

July 27, 2018

Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.

Consumer Products
0 0 0 0 0
0 comments

Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.

Consumer Products
0 0 0 0 0
0 comments
Jeff Parent B.

VP & Portf, Castlemoore Inc....

Price Price
$86.430
Owned Owned
Unknown

DON'T BUY
Celgene Corp(CELG-Q) 

July 18, 2018

The biotech sector is performing well.  He would prefer to own the XBI-N ETF to get a basket and diversify risk.  

Consumer Products
0 0 0 0 0
0 comments

The biotech sector is performing well.  He would prefer to own the XBI-N ETF to get a basket and diversify risk.  

Consumer Products
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$85.780
Owned Owned
No

PARTIAL BUY
Celgene Corp(CELG-Q) 

July 9, 2018

It is turning around.  It got hammered and is showing some potential.  It looks like it is breaking the downtrend.  He is keeping a sharp eye on it.  He is optimistic.

Consumer Products
0 0 0 0 0
0 comments

It is turning around.  It got hammered and is showing some potential.  It looks like it is breaking the downtrend.  He is keeping a sharp eye on it.  He is optimistic.

Consumer Products
0 0 0 0 0
0 comments
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$83.850
Owned Owned
Yes

HOLD
Celgene Corp(CELG-Q) 

July 5, 2018

Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)

Consumer Products
0 0 0 0 0
0 comments

Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)

Consumer Products
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$80.390
Owned Owned
No

WATCH
Celgene Corp(CELG-Q) 

June 20, 2018

He has started watching this bio-tech company as their earnings have been improving.  The technical chart looks bearish to him now.  He will watch them.  (Analysts’ price target is $114)

Consumer Products
0 0 0 0 0
0 comments

He has started watching this bio-tech company as their earnings have been improving.  The technical chart looks bearish to him now.  He will watch them.  (Analysts’ price target is $114)

Consumer Products
0 0 0 0 0
0 comments
Jason Del Vicar

Portfolio , HollisWealth...

Price Price
$79.770
Owned Owned
No

BUY
Celgene Corp(CELG-Q) 

June 14, 2018

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock.  This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.  

Consumer Products
0 0 0 0 0
0 comments

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock.  This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.  

Consumer Products
0 0 0 0 0
0 comments
Alex Ruus

Portfolio , Arrow Capital Manage...

Price Price
$78.390
Owned Owned
Unknown

TOP PICK
Celgene Corp(CELG-Q) 

May 30, 2018

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

Consumer Products
0 0 0 0 0
0 comments

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

Consumer Products
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$77.970
Owned Owned
Yes

PAST TOP PICK
Celgene Corp(CELG-Q) 

May 28, 2018

(A Top Pick May 28/17, Down 32%)  It is considered best of class but stumbled and there is a negative sentiment to health care stocks.  It is growing double digits but trading at a single digit multiple so he is just holding it for now.

Consumer Products
0 0 0 0 0
0 comments

(A Top Pick May 28/17, Down 32%)  It is considered best of class but stumbled and there is a negative sentiment to health care stocks.  It is growing double digits but trading at a single digit multiple so he is just holding it for now.

Consumer Products
0 0 0 0 0
0 comments
Teal Linde

Portfolio , Linde Equity Report...

Price Price
$78.630
Owned Owned
Yes

Showing 1 to 15 of 79 entries
Successfully Saved Company
Successfully Saved Company